Ju Yong Lim

Dr. Ju Yong Lim

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
JLJu Yong Lim
Ju Yong Lim
SPSung Jun Park
Sung Jun Park
HKHo Jin Kim
Ho Jin Kim
HKHee Jung Kim
Hee Jung Kim
SCSuk Jung Choo
Suk Jung Choo
JKJoon-bum Kim
Joon-bum Kim

1 March 2019 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
YOYou Jung Ok
You Jung Ok
SJSung-Ho Jung
Sung-Ho Jung
SLSeung-Whan Lee
Seung-Whan Lee
JAJung-Min Ahn
Jung-Min Ahn
JLJu Yong Lim
Ju Yong Lim
Background: Veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) is used in various cardiogenic shocks. In severe myocardial dysfunction, left heart (LH) distension may occur and aggravate pulmonary edema. Despite the recent case reports on various venting catheter insertion methods for LH decompression, the necessity and efficacy of LH venting procedure are still controversial. Therefore, we focused on evaluating efficacy of LH venting catheter insertion for LH decompression. Methods: In total, 373 patients received VA ECMO at our institution from May 2012 to January 2016. Of these, 25 patients underwent LH venting catheter insertion. Indication for the procedure included pulmonary congestion observed on chest radiogram, with arterial pulse pressure ≤10 mmHg. The control group comprised of 45 patients with peripheral VA ECMO having arterial pulse pressure ≤ for ≥24 hours during the same study period who did not undergo LH venting procedure. Finally, 70 patients were compared and analyzed. Results: Mean age of the patients was 52.6±17.1 years. The ECMO running time in each group was 7.2±7.1 days in the vent (−) group and 9.2±8.5 days in the vent (+) group. Successful weaning rate was higher in the LH vent (+) group (P=0.08). Moreover, LH venting catheter insertion was identified as a predictor of weaning success with marginal significance (OR =2.47; 95% CI: 0.90–6.72; P=0.07). Conclusions: LH decompression by venting catheter insertion in patients on VA ECMO may be more effective and helpful for successful ECMO weaning than conventional medical management without survival benefit.

25 April 2019 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
JLJu Yong Lim
Ju Yong Lim
PKPil Je Kang
Pil Je Kang
JKJoon Bum Kim
Joon Bum Kim
SJSung Ho Jung
Sung Ho Jung
SCSuk Jung Choo
Suk Jung Choo
JLJae Won Lee
Jae Won Lee

16 May 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
YKYun Seok Kim
Yun Seok Kim
JLJu Yong Lim
Ju Yong Lim

23 May 2022 in Trials
Verified
Journal Article
Open access
PDF file
HNHye Rim Na
Hye Rim Na
OKO Sung Kwon
O Sung Kwon
JKJoon Kyu Kang
Joon Kyu Kang
YKYong Han Kim
Yong Han Kim
JLJu Yong Lim
Ju Yong Lim
Background: Despite advances in surgical and postoperative care, myocardial injury or infarction (MI) is still a common complication in patients undergoing coronary artery bypass surgery (CABG). Several studies that aimed to reduce postoperative myocardial injury, including those investigating statin loading, have been conducted but did not indicate any clear benefits. Evolocumab, a PCSK9 inhibitor, has been reported to lower lipids and prevent ischemic events in various medical conditions. However, the effect of evolocumab in cardiovascular surgery has not been evaluated. The objective of this trial is to evaluate the cardioprotective effects of evolocumab in elective CABG patients with multivessel coronary artery disease. Methods: EVOCABG is a prospective, randomized, open, controlled, multicenter, superiority, phase III clinical trial. Patients with multivessel coronary artery disease without initial cardiac enzyme elevation will be recruited (n=100). Participants will be randomly allocated into two groups: a test group (evolocumab (140mg) administration once within 72 h before CABG) and a control group (no administration). The primary outcome is the change in peak levels of serum cardiac marker (troponin-I) within 3 days of CABG surgery compared to the baseline. Secondary outcomes include post-operative clinical events including death, myocardial infarction, heart failure, stroke, and atrial fibrillation. Discussion: This trial is the first prospective randomized controlled trial to demonstrate the efficacy of evolocumab in reducing ischemic-reperfusion injury in patients undergoing CABG. This trial will provide the first high-quality evidence for preoperative use of evolocumab in mitigating or preventing ischemic-reperfusion-related myocardial injury during the surgery. Trial registration: Clinical Research Information Service (CRIS) of the Republic of Korea KCT0005577. Registered on 4 November 2020.

1 November 2021 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
JLJiyun Lee
Jiyun Lee
YKYun Seok Kim
Yun Seok Kim
HKHwan Wook Kim
Hwan Wook Kim
JKJoon Kyu Kang
Joon Kyu Kang
HSHyun Song
Hyun Song
JLJu Yong Lim
Ju Yong Lim
Effect of revascularization on coronary chronic total occlusion in patients undergoing coronary artery bypass grafting Jiyun Lee, Yun Seok Kim, Hwan Wook Kim, Joon Kyu Kang, Hyun Song, Ju Yong Lim